Endo Pharmaceuticals Holdings (ENDP) Reports In-Line Q1 EPS; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts ENDP Hot Sheet
Price: $0.29 --0%
Financial Fact:
INTEREST EXPENSE, NET: 43.66M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
INTEREST EXPENSE, NET: 43.66M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q1 EPS of $0.87, in-line with the analyst estimate of $0.87. Revenue for the quarter came in at $691 million versus the consensus estimate of $700.34 million.
Endo Pharmaceuticals Holdings reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Endo Pharmaceuticals Holdings reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- L3Harris CEO steps down amid conduct review, shares drop
- BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c
- DA Davidson Reiterates Neutral Rating on Brunswick Corp (BC)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
